An open-label, Phase II randomised trial of Lapatinib (TYKERB™) + Pemetrexed (Alimta) versus Pemetrexed in the Second Line Treatment of advanced or metastatic Non Small Cell Lung Cancer.
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Lapatinib (Primary) ; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 09 Oct 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
- 09 Oct 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.